Literature DB >> 33497419

High genetic variability of Schmallenberg virus M-segment leads to efficient immune escape from neutralizing antibodies.

Kerstin Wernike1, Ilona Reimann1, Ashley C Banyard2, Franziska Kraatz1, S Anna La Rocca2, Bernd Hoffmann1, Sarah McGowan2, Silke Hechinger1, Bhudipa Choudhury2, Andrea Aebischer3, Falko Steinbach2,4, Martin Beer1.   

Abstract

Schmallenberg virus (SBV) is the cause of severe fetal malformations when immunologically naïve pregnant ruminants are infected. In those malformed fetuses, a "hot-spot"-region of high genetic variability within the N-terminal region of the viral envelope protein Gc has been observed previously, and this region co-localizes with a known key immunogenic domain. We studied a series of M-segments of those SBV variants from malformed fetuses with point mutations, insertions or large in-frame deletions of up to 612 nucleotides. Furthermore, a unique cell-culture isolate from a malformed fetus with large in-frame deletions within the M-segment was analyzed. Each Gc-protein with amino acid deletions within the "hot spot" of mutations failed to react with any neutralizing anti-SBV monoclonal antibodies or a domain specific antiserum. In addition, in vitro virus replication of the natural deletion variant could not be markedly reduced by neutralizing monoclonal antibodies or antisera from the field. The large-deletion variant of SBV that could be isolated in cell culture was highly attenuated with an impaired in vivo replication following the inoculation of sheep. In conclusion, the observed amino acid sequence mutations within the N-terminal main immunogenic domain of glycoprotein Gc result in an efficient immune evasion from neutralizing antibodies in the special environment of a developing fetus. These SBV-variants were never detected as circulating viruses, and therefore should be considered to be dead-end virus variants, which are not able to spread further. The observations described here may be transferred to other orthobunyaviruses, particularly those of the Simbu serogroup that have been shown to infect fetuses. Importantly, such mutant strains should not be included in attempts to trace the spatial-temporal evolution of orthobunyaviruses in molecular-epidemiolocal approaches during outbreak investigations.

Entities:  

Year:  2021        PMID: 33497419      PMCID: PMC7872300          DOI: 10.1371/journal.ppat.1009247

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  55 in total

1.  Phylogeny of the Simbu serogroup of the genus Bunyavirus.

Authors:  Mohammad F Saeed; Li Li; Heiman Wang; Scott C Weaver; Alan D T Barrett
Journal:  J Gen Virol       Date:  2001-09       Impact factor: 3.891

2.  Genetically stable infectious Schmallenberg virus persists in foetal envelopes of pregnant ewes.

Authors:  Antoine Poskin; Ludovic Martinelle; Yves Van der Stede; Claude Saegerman; Brigitte Cay; Nick De Regge
Journal:  J Gen Virol       Date:  2017-07-12       Impact factor: 3.891

Review 3.  Detection of Schmallenberg virus serum neutralising antibodies.

Authors:  Karen L Mansfield; S Anna La Rocca; Meenakshi Khatri; Nicholas Johnson; Falko Steinbach; Anthony R Fooks
Journal:  J Virol Methods       Date:  2012-11-29       Impact factor: 2.014

4.  Incursion of Schmallenberg virus into Great Britain in 2011 and emergence of variant sequences in 2016.

Authors:  S L McGowan; S A La Rocca; S S Grierson; A Dastjerdi; B Choudhury; F Steinbach
Journal:  Vet J       Date:  2018-02-08       Impact factor: 2.688

5.  Diagnosis of Schmallenberg virus infection in malformed lambs and calves and first indications for virus clearance in the fetus.

Authors:  Nick De Regge; Thierry van den Berg; Laura Georges; Brigitte Cay
Journal:  Vet Microbiol       Date:  2012-11-29       Impact factor: 3.293

6.  The effect of proteolytic cleavage of La Crosse virus G1 glycoprotein on antibody neutralization.

Authors:  L Kingsford; D W Hill
Journal:  J Gen Virol       Date:  1983-10       Impact factor: 3.891

7.  Novel orthobunyavirus in Cattle, Europe, 2011.

Authors:  Bernd Hoffmann; Matthias Scheuch; Dirk Höper; Ralf Jungblut; Mark Holsteg; Horst Schirrmeier; Michael Eschbaumer; Katja V Goller; Kerstin Wernike; Melina Fischer; Angele Breithaupt; Thomas C Mettenleiter; Martin Beer
Journal:  Emerg Infect Dis       Date:  2012-03       Impact factor: 6.883

8.  A novel panel of monoclonal antibodies against Schmallenberg virus nucleoprotein and glycoprotein Gc allows specific orthobunyavirus detection and reveals antigenic differences.

Authors:  Kerstin Wernike; Emiliana Brocchi; Paolo Cordioli; Yann Sénéchal; Christian Schelp; Anne Wegelt; Andrea Aebischer; Gleyder Roman-Sosa; Ilona Reimann; Martin Beer
Journal:  Vet Res       Date:  2015-03-11       Impact factor: 3.683

9.  Orthobunyavirus spike architecture and recognition by neutralizing antibodies.

Authors:  Jan Hellert; Andrea Aebischer; Kerstin Wernike; Ahmed Haouz; Emiliana Brocchi; Sven Reiche; Pablo Guardado-Calvo; Martin Beer; Félix A Rey
Journal:  Nat Commun       Date:  2019-02-20       Impact factor: 14.919

10.  Evolutionary dynamics of West Nile virus in the United States, 1999-2011: phylogeny, selection pressure and evolutionary time-scale analysis.

Authors:  Germán Añez; Andriyan Grinev; Caren Chancey; Christopher Ball; Namita Akolkar; Kevin J Land; Valerie Winkelman; Susan L Stramer; Laura D Kramer; Maria Rios
Journal:  PLoS Negl Trop Dis       Date:  2013-05-30
View more
  2 in total

1.  Failure to detect Schmallenberg virus RNA in ram semen in the UK (2016-2018).

Authors:  Alice Curwen; Scott Jones; Ceri Stayley; Laura Eden; Heather McKay; Peers Davies; Fiona Lovatt; Stephen Dunham; Rachael Tarlinton
Journal:  Vet Rec Open       Date:  2022-06-20

2.  Identification and Genetic Characterization of Viral Pathogens in Ruminant Gestation Abnormalities, Israel, 2015-2019.

Authors:  Natalia Golender; Velizar Bumbarov; Anita Kovtunenko; Dan David; Marisol Guini-Rubinstein; Asaf Sol; Martin Beer; Avi Eldar; Kerstin Wernike
Journal:  Viruses       Date:  2021-10-22       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.